REBECCA HARRIS: Open Payments
NPI 1629014352 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$633 in 34 payments from 10 companies in 2025. Trend: 2023 $429 · 2024 $301 · 2025 $633
Food & beverage: $633
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 17 | $324 |
| Astellas Pharma US Inc | 7 | $122 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
| Exeltis, USA Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $20 |
| ABBVIE INC. | 1 | $19 |
| SHIELD THERAPEUTICS INC | 1 | $19 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $16 |
| Amgen Inc. | 1 | $14 |
Products named: MYFEMBREE, GEMTESA, Veozah, Mirena, SLYND, Qelbree, ZURZUVAE, UBRELVY.
Industry payments across AL — which companies pay providers there.
